Cargando…

Interaction Between SARS-CoV-2 and Pathogenic Bacteria

The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazel, Parvindokht, Sedighian, Hamid, Behzadi, Elham, Kachuei, Reza, Imani Fooladi, Abbas Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206355/
https://www.ncbi.nlm.nih.gov/pubmed/37222840
http://dx.doi.org/10.1007/s00284-023-03315-y
_version_ 1785046211605037056
author Fazel, Parvindokht
Sedighian, Hamid
Behzadi, Elham
Kachuei, Reza
Imani Fooladi, Abbas Ali
author_facet Fazel, Parvindokht
Sedighian, Hamid
Behzadi, Elham
Kachuei, Reza
Imani Fooladi, Abbas Ali
author_sort Fazel, Parvindokht
collection PubMed
description The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possible co-occurrence of the infection with other viral and bacterial pathogens is investigated. Respiratory infections predispose patients to co‐infections and these lead to increased disease severity and mortality. Numerous types of antibiotics have been employed for the prevention and treatment of bacterial co‐infection and secondary bacterial infections in patients with a SARS-CoV-2 infection. Although antibiotics do not directly affect SARS‐CoV‐2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co‐infection rather than virus itself. Therefore, bacterial co‐infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID‐19. In this review, we will summarize the bacterial co‐infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID‐19.
format Online
Article
Text
id pubmed-10206355
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-102063552023-05-25 Interaction Between SARS-CoV-2 and Pathogenic Bacteria Fazel, Parvindokht Sedighian, Hamid Behzadi, Elham Kachuei, Reza Imani Fooladi, Abbas Ali Curr Microbiol Review Article The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possible co-occurrence of the infection with other viral and bacterial pathogens is investigated. Respiratory infections predispose patients to co‐infections and these lead to increased disease severity and mortality. Numerous types of antibiotics have been employed for the prevention and treatment of bacterial co‐infection and secondary bacterial infections in patients with a SARS-CoV-2 infection. Although antibiotics do not directly affect SARS‐CoV‐2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co‐infection rather than virus itself. Therefore, bacterial co‐infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID‐19. In this review, we will summarize the bacterial co‐infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID‐19. Springer US 2023-05-24 2023 /pmc/articles/PMC10206355/ /pubmed/37222840 http://dx.doi.org/10.1007/s00284-023-03315-y Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Fazel, Parvindokht
Sedighian, Hamid
Behzadi, Elham
Kachuei, Reza
Imani Fooladi, Abbas Ali
Interaction Between SARS-CoV-2 and Pathogenic Bacteria
title Interaction Between SARS-CoV-2 and Pathogenic Bacteria
title_full Interaction Between SARS-CoV-2 and Pathogenic Bacteria
title_fullStr Interaction Between SARS-CoV-2 and Pathogenic Bacteria
title_full_unstemmed Interaction Between SARS-CoV-2 and Pathogenic Bacteria
title_short Interaction Between SARS-CoV-2 and Pathogenic Bacteria
title_sort interaction between sars-cov-2 and pathogenic bacteria
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206355/
https://www.ncbi.nlm.nih.gov/pubmed/37222840
http://dx.doi.org/10.1007/s00284-023-03315-y
work_keys_str_mv AT fazelparvindokht interactionbetweensarscov2andpathogenicbacteria
AT sedighianhamid interactionbetweensarscov2andpathogenicbacteria
AT behzadielham interactionbetweensarscov2andpathogenicbacteria
AT kachueireza interactionbetweensarscov2andpathogenicbacteria
AT imanifooladiabbasali interactionbetweensarscov2andpathogenicbacteria